Baseline susceptibility of primary HIV-2 to entry inhibitors.
about
Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applicationsRare HIV-1 Subtype J Genomes and a New H/U/CRF02_AG Recombinant Genome Suggests an Ancient Origin of HIV-1 in AngolaEvolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response.Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses.HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates.A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support.A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity.Development of water-soluble polyanionic carbosilane dendrimers as novel and highly potent topical anti-HIV-2 microbicides.Evaluation of the fusion inhibitor P3 peptide as a potential microbicide to prevent HIV transmission in women.
P2860
Q30366071-09A7B567-C345-4002-BAB2-66D2E2DF6EE4Q30387160-EAE7B084-0769-453D-8B7F-B804779C70EAQ33591409-835105C2-DADA-486A-866E-94462ED0126AQ34992731-9471C779-54A8-4AFF-B880-24C68369D949Q35134947-60EC9EA0-A98C-4061-851A-B1B86766DA0DQ35738681-0168C126-F609-4E4A-9DB8-9BBAD02C94D2Q37448301-621D93D0-575C-4AB3-B244-A379D735DAEAQ37512840-36D3A83E-4044-40E7-8F3E-F1D31A18ABE0Q37517645-61B9DD81-3043-4D8D-ADC5-FC7EEC571CCCQ40267838-FCCE2350-6717-495F-A3C4-CF82E60EBE93Q41051936-B9F67B74-EF99-40E6-AB9D-549D15A440A4Q52580522-37EA1C79-FD5E-4A40-A6AB-0A6275E0565B
P2860
Baseline susceptibility of primary HIV-2 to entry inhibitors.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Baseline susceptibility of primary HIV-2 to entry inhibitors.
@en
type
label
Baseline susceptibility of primary HIV-2 to entry inhibitors.
@en
prefLabel
Baseline susceptibility of primary HIV-2 to entry inhibitors.
@en
P2093
P50
P356
P1433
P1476
Baseline susceptibility of primary HIV-2 to entry inhibitors.
@en
P2093
Fernando Maltez
Manuela Doroana
Patrícia Cavaco-Silva
Umbelina Caixas
P304
P356
10.3851/IMP1996
P50
P577
2012-01-25T00:00:00Z